| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_132aa5ddba376cda52c2bedb26765245 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-24 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56 |
| filingDate |
2004-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2008-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2bd7bc83d36f508a5f827ad0ecb27d1a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09427ec027a0d4672f7869f873d80a0f |
| publicationDate |
2008-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
DE-102004019743-B4 |
| titleOfInvention |
Multiphase preparation for contraception based on natural estrogen |
| abstract |
Multiphase preparation for contraception characterized in that the first phase consists of 2 daily doses of natural estrogen estradiol valerate to 3 mg, a second phase consists of 2 groups of daily dose units, wherein the first group consists of 5 daily dose units of a combination of 2 mg estradiol valerate and twice or three times the ovulation inhibition dose of the synthetic progestin dienogest or drospirenone and the second group is formed from 17 daily dose units of a combination of 2 mg estradiol valerate and three or four times the ovulation inhibitor dose of dienogest or drospirenone, a third phase consists of 2 daily doses of 1 mg estradiol valerate and another phase consists of 2 daily doses of pharmaceutically acceptable placebo. |
| priorityDate |
2004-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |